All In Biotech

Drug Trial Radar · NCT00410761

An Efficacy Study Comparing ZD6474 to Placebo in Medullary Thyroid Cancer

An International, Phase III, Randomized, Double-Blinded, Placebo-Controlled, Multi-Center Study to Assess the Efficacy of ZD6474 (ZACTIMATM) Versus Placebo in Subjects With Unresectable Locally Advanced or Metastatic Medullary Thyroid Cancer

Last checked: Nov 20, 2026Latest source record: Sep 24, 2025 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedResults posted on the registryPivotal-lookingPhase 3. Randomized with 331 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

331

Actual

Start

Nov 23, 2006

Primary completion

Jul 31, 2009

Study completion Jul 26, 2024

Sponsor

Lead sponsor
Genzyme, a Sanofi CompanySanofi (SNY)
Sponsor type
Industry
First posted
Dec 13, 2006

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
Quadruple (participant, care provider, investigator, outcomes assessor)
Primary purpose
Treatment
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The purpose of this study is to learn how hereditary or sporadic medullary thyroid cancer patients, treated with ZD6474, react to the drug, what happens to ZD6474 in the human body, about the side effects of ZD6474, and if ZD6474 can decrease or prevent the growth of tumors.

Conditions

  • Thyroid Cancer

Interventions

  • ZD6474 (Vandetanib)Drug

    once daily oral tablet

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Progression-Free Survival(PFS)Time frame: RECIST tumour assessments were performed at screening (within 3 weeks before date of randomisation), then once every 12 weeks up to and including discontinuation of blinded study treatment, unless patients had withdrawn consent.

Locations

127 sites in 24 countries. Site status is shown where the registry gives one.

  • Investigational Site Number 3

    Little Rock, Arkansas

  • University Arkansas Site Number : 3

    Little Rock, Arkansas

  • Investigational Site Number 8

    San Francisco, California

  • USCF / Mt Zion Medical Center Site Number : 8

    San Francisco, California

  • Investigational Site Number 9

    Aurora, Colorado

  • University Of Colorado Health Sciences Center Site Number : 9

    Aurora, Colorado

  • Investigational Site Number 11

    New Haven, Connecticut

  • Yale University School Medicine Site Number : 11

    New Haven, Connecticut

  • Investigational Site Number 15

    Jacksonville, Florida

  • Mayo Clinic- Site Number : 15

    Jacksonville, Florida

  • Investigational Site Number 18

    Chicago, Illinois

  • The University Of Chicago Site Number : 18

    Chicago, Illinois

  • Investigational Site Number 17

    Lexington, Kentucky

  • The University Of Kentucky Site Number : 17

    Lexington, Kentucky

  • Dana Farber Cancer Institute Site Number : 2

    Boston, Massachusetts

  • Investigational Site Number 2

    Boston, Massachusetts

  • Investigational Site Number 7

    Detroit, Michigan

  • Wayne State University / Harper Hospital Site Number : 7

    Detroit, Michigan

  • Investigational Site Number 14

    Rochester, Minnesota

  • Mayo Clinic- Site Number : 14

    Rochester, Minnesota

  • Investigational Site Number 10

    St Louis, Missouri

  • Washington University School Of Med Site Number : 10

    St Louis, Missouri

  • Investigational Site Number 6

    Cincinnati, Ohio

  • University Of Cincinnati Site Number : 6

    Cincinnati, Ohio

  • Investigational Site Number 22

    Portland, Oregon

  • Oregon Health & Science University- Site Number : 22

    Portland, Oregon

  • Investigational Site Number 19

    Charleston, South Carolina

  • Medical University of South Carolina- Site Number : 19

    Charleston, South Carolina

  • Anderson Cancer Center Site Number : 13

    Houston, Texas

  • Investigational Site Number 13

    Houston, Texas

  • Fletcher Allen Health Care Site Number : 21

    Burlington, Vermont

  • Investigational Site Number 21

    Burlington, Vermont

  • Investigational Site Number 1001

    St Leonards, Australia

  • Investigational Site Number 1901

    Vienna, Austria

  • Investigational Site Number : 1901

    Vienna, Austria

  • Investigational Site Number : 1101

    Anderlecht, Belgium

  • Investigational Site Number 1101

    Brussels, Belgium

  • Investigational Site Number 1102

    Leuven, Belgium

  • Investigational Site Number : 1102

    Leuven, Belgium

  • Investigational Site Number 2301

    Porto Alegre, Brazil

Showing 40 of 127 sites, US sites first. The full list is on the registry record.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.